StockDuty ← Dashboard Nov 11, 2026 11:30 AM ET
SignalCorporate

MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability

MaxCyte targets $34.5M 2026 revenue with Akron Bio deal to accelerate profitability.

Context
What happened: MaxCyte (MXCT) said it entered a definitive agreement to acquire Akron Bio from Arcline Investment Management, following a competitive process. Key numbers: MaxCyte outlined at least $34.5M in 2026 revenue. Akron's revenue is expected to be $28 million for 2026. Why it matters: MaxCyte said the Akron Bio deal is intended to accelerate profitability.
What changed
MaxCyte (MXCT) said it entered a definitive agreement to acquire Akron Bio from Arcline Investment Management, following a competitive process.
Why it matters
MaxCyte said the Akron Bio deal is intended to accelerate profitability.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →